CHRONIC ACTINIC DERMATITIS
1
DEFINITION:
It is a common eczematous photodermatosis
i.e., an itchy, inflammatory skin disorder
caused due to sun exposur...
3
ETIOLOGY:
Action Spectrum- UVA, UVB, Visible light.
PREDISPOSING CONDITIONS:
 Allergic contact dermatitis
 Drug induce...
4
PATHOGENESIS:
 Presence of predominantly CD8+ cytotoxic
suppressor cells results in developing
CAD from pre existing di...
5
DNA of normal
skin cells
Altered to
become an
antigen
Delayed type of
Hypersensitivity
reaction
UV
Radiation
CLINICAL FEATURES:
 Itchy, confluent eczematous patches seen
over photo exposed sites
 Often a sharp border at the edge ...
7
8
VARIANTS:
 Actinic Reticuloid
 Persistent light reactors
 Photosensitivity Dermatitis and Eczema
DIAGNOSIS:
Based on
...
DIFFERENTIAL DIAGNOSIS
9
10
INVESTIGATIONS:
 Histopathology:
 In mild cases- chronic eczema, acanthosis and
spongiosis are seen.
 In severe CAD ...
11
12
 PHOTO TESTING:
Photo provocation is performed on uninvolved
skin. An eczematous response to UVB in majority
and to UV...
13
14
 TREATMENT:
 Absolute photoprotection .
 Usage of broad spectrum sunscreens.
 Topical steroids in mild cases.
 Top...
15
Upcoming SlideShare
Loading in …5
×

Chronic actinic dermatitis

2,397 views

Published on

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
2,397
On SlideShare
0
From Embeds
0
Number of Embeds
12
Actions
Shares
0
Downloads
44
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Chronic actinic dermatitis

  1. 1. CHRONIC ACTINIC DERMATITIS 1
  2. 2. DEFINITION: It is a common eczematous photodermatosis i.e., an itchy, inflammatory skin disorder caused due to sun exposure persisting for long term. 2
  3. 3. 3 ETIOLOGY: Action Spectrum- UVA, UVB, Visible light. PREDISPOSING CONDITIONS:  Allergic contact dermatitis  Drug induced photosensitivity  Endogenous eczema  Air borne contact dermatitis  HIV Infection  Photoaged and aged skin.
  4. 4. 4 PATHOGENESIS:  Presence of predominantly CD8+ cytotoxic suppressor cells results in developing CAD from pre existing disorders.  CAD may develop as delayed type of hypersensitivity reaction during initial localized photo allergic reaction to a normal skin altered to become antigenic by light or hapten binding to endogenous carrier protein through UVA dependent covalent photochemical reaction. DNA is the prime target.
  5. 5. 5 DNA of normal skin cells Altered to become an antigen Delayed type of Hypersensitivity reaction UV Radiation
  6. 6. CLINICAL FEATURES:  Itchy, confluent eczematous patches seen over photo exposed sites  Often a sharp border at the edge of clothing  Sparing of upper eyelids, retroauricular and submental region, finger webs, depth of skin creases.  Erythematous plaques with shiny infiltrated papules may develop.  Lichenification over period of time. 6
  7. 7. 7
  8. 8. 8 VARIANTS:  Actinic Reticuloid  Persistent light reactors  Photosensitivity Dermatitis and Eczema DIAGNOSIS: Based on  Clinical examination  Histology-chronic eczema with or without lymphoma like changes.  Photobiologic- reduction in MED of UVB, UVA on normal skin.
  9. 9. DIFFERENTIAL DIAGNOSIS 9
  10. 10. 10 INVESTIGATIONS:  Histopathology:  In mild cases- chronic eczema, acanthosis and spongiosis are seen.  In severe CAD Pautrier like microabcesses seen in epidermis.  An upper dermal dense lymphocytic perivascular infiltration seen.  Eosinophils, macrophages, plasma cells may be present.  In Actinic Reticuloid it resembles T cell lymphoma except mitotic figures are less frequent.
  11. 11. 11
  12. 12. 12  PHOTO TESTING: Photo provocation is performed on uninvolved skin. An eczematous response to UVB in majority and to UVA,VR in less patients. The MED of UVB is reduced in 70% & UVA in 33% of patients.  PATCH TEST and PHOTOPATCH TEST: To detect allergens like oleoresins, compositae sunscreens etc.  Blood tests: Circulating Antinuclear antibodies. CD8+ sezary cells in the absence of malignancy.
  13. 13. 13
  14. 14. 14  TREATMENT:  Absolute photoprotection .  Usage of broad spectrum sunscreens.  Topical steroids in mild cases.  Topical use of Tacrolimus.  In moderate to severe cases: Azathioprine- 1.5 to 2.5 mg/kg/day Cyclosporine- 3.5 to 5 mg/kg/day  PUVA therapy
  15. 15. 15

×